Proteomics International Laboratories (ASX:PIQ) is a wholly owned subsidiary and trading name of PILL, a medical technology company at the forefront of predictive diagnostics and bioanalytical services. The Company specialises in the area of proteomics - the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.
Proteomics International Laboratories Ltd ((ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, is pleased to announce that its subsidiary OxiDx Pty Ltd, has secured new intellectual property protection following the grant of a patent in China for the platform technology which precisely measures levels of oxidative stress.
On 22 April 2025, Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) announced that it will be conducting a placement of 10,810,811 fully paid ordinary shares in the Company at an issue price of $0.37 per Share to sophisticated, institutional and professional investors, raising approximately $4 million.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics is pleased to provide the following update on its business activities for the three months to 31 March 2025 and subsequent to the period end.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) is pleased to announce that it has received firm commitments from new and existing investors and Directors and Key Management Personnel for a non-underwritten placement of approximately 12.1 million new fully paid ordinary shares at $0.37 per New Share.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, will give an investor briefing at the Alpha ex-100 Conference hosted by Morgan Stanley in Sydney today.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) is pleased to announce the formation of its Clinical Advisory Board for its world-first diagnostic blood test to identify esophageal cancer, specifically esophageal adenocarcinoma, PromarkerEso.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics has secured new intellectual property protection following the grant of a patent in Australia for the platform technology which precisely measures levels of oxidative stress.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) is pleased to release a copy of the presentation to be provided by Dr Richard Lipscombe to attendees of the WA Life Sciences Broker Meets Biotech event, Perth on 20th March 2025.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, is pleased to announce the official launch of its first-in-class predictive test for diabetic kidney disease, Promarker(R)D, in Australia.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) is pleased to announce the publication of results of its landmark study demonstrating the PromarkerD test significantly outperforms the current standard of care tests in predicting future kidney function decline.
Correction - Notice of Extraordinary General Meeting/Proxy
Notice of Extraordinary General Meeting/Proxy Form
Investor Presentation - JMM Biotech Forum
Interim Financial Report and Appendix 4D
Notice of Annual General Meeting/Proxy Form
